Geriatric 8 screening of frailty in patients with prostate cancer

Objectives To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer. Methods Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone‐naïve prostate cancer or castration‐resistant prostate cancer. The primary purpose was the association between frailty (Geriatric 8 ≤14) and robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone, and metastatic diseases. Secondary purposes included a comparison of the Geriatric 8 scores among the disease status and the influence of Geriatric 8 score on overall survival. Results The median age was 75 years. Geriatric 8 scores ≤14 were seen in 36% of robot‐assisted radical prostatectomy (n = 78/214), 57% of radiotherapy (n = 119/209), 91% of androgen deprivation therapy alone (n = 19/21) and 70% of metastatic diseases (n = 67/96). The median Geriatric 8 score in patients treated with robot‐assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and metastatic diseases was 15.0, 14.0, 12.0 and 12.8, respectively. The median Geriatric 8 score was significantly higher in the metastatic disease than that in localized disease (14.5 vs 12.8, respectively). Robot‐assisted radical prostatectomy patients had a significantly higher Geriatric 8 score than radiotherapy patients, with the cut‐off value of 13 in metastatic hormone‐naïve prostate cancer patients, and between Geriatric 8 scores ≤12 and >12 in castration‐resistant prostate cancer patients. Conclusion The Geriatric 8 score is significantly associated with treatment by disease stages in patients with prostate cancer.